Molecular imaging with infliximab antibody with FITC has the potential to predict therapeutic responses to infliximab antibody and can be used for personalized medicine in ulcerative colitis.

Inclusion Criteria:

• Patients with active ulcerative colitis will receive infliximab antibody therapy.

Exclusion Criteria:

• Patients with impaired blood clotting.
• Patients with short bowel syndrome.
• Patients during the pregnancy and lactation period.
• Patients received enema therapy within 1 month before inclusion in the study, or had anti-TNF therapy within the last 12 months.
• Patients participated in another clinical trial or administrated other investigational drugs within 4 months prior to the screening visit.
• Patients with moderate to severe heart failure, active tuberculosis or acute infections.

Patients with active ulcerative colitis will receive infliximab antibody therapy.